Skip to content

tDCS for phobic postural vertigo

tDCS for phobic postural vertigo - tDCS-PPV

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011844
Enrollment
20
Registered
2017-03-07
Start date
2017-03-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F45.8

Interventions

Group 1: Block 1 (3-4 Wochen): Wash-out Phase after enrolment. Only psycho-education as Intervention. Then follow-up. Block 2: active tDCS, anode F3, cathode AF8, 5 Treatments, 30 min each, 2 mA curre

Sponsors

Klinikum der Universität München, Campus Großhadern
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: patients (male/female) in Age 18-50. Secondary somatoform vertigo since <2 years with gait disturbance without objectively measurable or visible disturbance of gait and posture. Vertigo is described as dizziness with undulating incapability of gait and posture, fear attacks without dropping, partially described also as Body sway. Dizziness is modulated by the Situation. Vestibular diagnostics without pathology (calorics, head Impulse test, oculomotorics, subjetive visual vertical, Scanning Laser Ophtalmoskop , Video oculography), no pathology in posturography except for typical PPV pattern. No medication (e.g. selective Serotonin reuptake inhibitor).

Exclusion criteria

Exclusion criteria: Alcohol or drug abuse, pregnancy, other psychiatric disorder, post stroke, malignant diseases, electronic or metal implants.

Design outcomes

Primary

MeasureTime frame
active Stimulation is superior to sham Stimulation in Terms of reduction of diziness and anxiety (questionnaires: DHI, BDI, HADS, WHOQoL) at the time Point of follow-up (3-4 weeks after Stimulation).

Secondary

MeasureTime frame
active Stimulation is superior to sham Stimulation in Terms of reduction of posturography measures, VOG, SLO at the time Point of follow-up (3-4 weeks after Stimulation).

Countries

Germany

Contacts

Public ContactValerie Kirsch

Neurologische Klinik der Universität München

valerie.kirsch@med.uni-muenchen.de089/4400-74842

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026